Abstract | BACKGROUND: METHODS:
Type 1 diabetes mellitus was induced in Sprague-Dawley rats by a single intravenous injection of 60 mg/kg STZ. To produce the I/R injury, the left anterior descending coronary artery was occluded for 45 minutes, followed by 2 hours of reperfusion. CAPA was pretreated intraperitoneally 30 minutes before reperfusion. An analog devoid of the antioxidant property of CAPA, dimethoxyl CAPA (dmCAPA), and a nitric oxide synthase (NOS) inhibitor (Nω-nitro- l-arginine methyl ester [ l-NAME]) were used to evaluate the mechanism involved in the reduction of the infarct size following CAPA-treatment. Finally, the cardioprotective effect of chronic treatment of CAPA was analyzed in diabetic rats. RESULTS: Compared to the control group, CAPA administration (3 and 15 mg/kg) significantly reduced the myocardial infarct size after I/R, while dmCAPA (15 mg/kg) had no cardioprotective effect. Interestingly, pretreatment with a NOS inhibitor, ( L-NAME, 3 mg/kg) eliminated the effect of CAPA on myocardial infarction. Additionally, a 4-week CAPA treatment (1 mg/kg, orally, once daily) started 4 weeks after STZ-induction could effectively decrease the infarct size and ameliorate the cardiac dysfunction by pressure-volume loop analysis in STZ-induced diabetic animals. CONCLUSIONS: CAPA, which is structurally similar to CAPE, exerts cardioprotective activity in I/R injury through its antioxidant property and by preserving nitric oxide levels. On the other hand, chronic CAPA treatment could also ameliorate cardiac dysfunction in diabetic animals.
|
Authors | Yi-Jin Ho, An-Sheng Lee, Wen-Pin Chen, Wei-Lung Chang, Ying-Kang Tsai, Hsi-Lin Chiu, Yueh-Hsiung Kuo, Ming-Jai Su |
Journal | Cardiovascular diabetology
(Cardiovasc Diabetol)
Vol. 13
Pg. 98
(Jun 12 2014)
ISSN: 1475-2840 [Electronic] England |
PMID | 24923878
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Caffeic Acids
- Hypoglycemic Agents
- caffeic acid phenethyl amide
|
Topics |
- Animals
- Caffeic Acids
(therapeutic use)
- Diabetes Mellitus, Experimental
(drug therapy, pathology)
- Hypoglycemic Agents
(therapeutic use)
- Male
- Myocardial Infarction
(pathology, prevention & control)
- Myocardial Reperfusion Injury
(pathology, prevention & control)
- Rats
- Rats, Sprague-Dawley
|